Enlivex Ltd
1BT
Company Profile
Business description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Contact
14 Einstein Street
Weizmann Science Park
Ness Ziona7403618
ISRT: +972 86328500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
Stronger copper, aluminum and zinc prices offset by iron ore.
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
Leading AI labs are building economic moats to stave off commodification threats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.50 | 19.50 | -0.22% |
| CAC 40 | 7,832.88 | 29.55 | 0.38% |
| DAX 40 | 25,277.68 | 190.41 | 0.76% |
| Dow JONES (US) | 51,850.55 | 195.60 | 0.38% |
| FTSE 100 | 10,656.28 | 104.23 | 0.99% |
| HKSE | 24,150.24 | 120.96 | -0.50% |
| NASDAQ | 27,245.90 | 120.27 | -0.44% |
| Nikkei 225 | 67,522.54 | 1,508.38 | -2.19% |
| NZX 50 Index | 13,749.51 | 78.11 | -0.56% |
| S&P 500 | 7,807.24 | 4.30 | -0.06% |
| S&P/ASX 200 | 8,773.00 | 10.20 | -0.12% |
| SSE Composite Index | 3,787.16 | 10.09 | -0.27% |